Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy

Abstract Background CRISPR-Cas13a is renowned for its precise and potent RNA editing capabilities in cancer therapy. While various material systems have demonstrated efficacy in supporting CRISPR-Cas13a to execute cellular functions in vitro efficiently and specifically, the development of CRISPR-Ca...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mingkang Liang, Yongqiang Wang, Lisha Liu, Dashi Deng, Zeqin Yan, Lida Feng, Chenfan Kong, Chenchen Li, Yuqing Li, Guangzhi Li
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-08-01
Serija:	Journal of Experimental & Clinical Cancer Research
Teme:	CRISPR-Cas13a Flubendazole Fluorinated chitosan Bladder cancer Programmed death ligand 1 Transmembrane peptides
Online dostop:	https://doi.org/10.1186/s13046-024-03146-0
Oznake:	Označite Brez oznak, prvi označite!